}}</ref> and its medical use remains mostly confined to that country. Its [[muscle relaxant]] properties are approximately equivalent to those of [[diazepam]] - however, it has more powerful [[sedative]], [[hypnotic]], [[anxiolytic]] and [[anticonvulsant]] effects and is around four times more potent by weight compared to diazepam.<ref>{{Cite journal | doi = 10.1254/fpj.76.447 | last1 = Sukamoto | first1 = T. | last2 = Aikawa | first2 = K. | last3 = Itoh | first3 = K. | last4 = Nose | first4 = T. | title = [Psycopharmacological and general pharmacological studies of 7-chloro-1-cyclopropylmethyl-1, 3-dihydro-5-(2-fluorophenyl)-2H-1, 4-benzodiazepin-2-one (KB-509) (author's transl)] | journal = Nippon Yakurigaku Zasshi | volume = 76 | issue = 6 | pages = 447–68 |date=Sep 1980 | pmid = 7203280 }}</ref> It is longer acting than diazepam due to its long-acting active metabolites,<ref>{{Cite journal | doi = 10.1254/fpj.80.15 | last1 = Ueki | first1 = S. | last2 = Sukamoto | first2 = T. | last3 = Watanabe | first3 = S. | last4 = Yamamoto | first4 = T. | last5 = Kataoka | first5 = Y. | last6 = Shibata | first6 = S. | last7 = Suwandi | first7 = D. | last8 = Shibata | first8 = K. | last9 = Takano | first9 = M. | last10 = Sukamoto | first10 = Takayuki | title = [Behavioral effects of flutoprazepam (KB-509) and its metabolites] | journal = Nippon Yakurigaku Zasshi | volume = 80 | issue = 1 | pages = 15–30 |date=Jul 1982 | pmid = 6890927 | display-authors = 8 }}</ref> which contribute significantly to its effects.<ref>{{Cite journal | doi = 10.1007/BF03190114 | last1 = Barzaghi | first1 = N. | last2 = Leone | first2 = L. | last3 = Monteleone | first3 = M. | last4 = Tomasini | first4 = G. | last5 = Perucca | first5 = E. | title = Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects. | journal = Eur J Drug Metab Pharmacokinet | volume = 14 | issue = 4 | pages = 293–8 | pmid = 2633923 | year = 1989 }}</ref>
